Kidney Cancer Treatment Options

jnf

All FDA approaved treatments for renal cell carcinoma.

TREATMENT	DRUG NAME(S)	TREATMENT TYPE	MANUFACTURER	FDA APPROVAL	TYPICAL USE
Yervoy/Opdivo	Ipilimumab/ Nivolumab	Immunotherapy: Anti-CTLA4 inhibitor/ Anti-PD1 Checkpoint inhibitor Infusion	Bristol Myers Squibb	2018 approval for first line intermediate and high risk metastatic RCC patients	1st line
Cabometyx/Opdivo	Cabozantinib/ Nivolumab	Targeted Therapy + Anti-PD1 Immunotherapy	Exelixis/BMS	2021 approval for first line treatment of Metastatic RCC	1st line
Keytruda/Lenvima	Pembrolizumab/ Lenvatinib	Immunotherapy + Targeted Therapy Infusion/Oral	Merck/Eisai	2021 approval for first line treatment of metastatic RCC	1st line
Keytruda/Inlyta	Pembrolizumab/ Axitinib	Immunotherapy + Targeted Therapy Infusion and oral medication	Merck/Pfizer	2019 approval for first line therapy of metastatic RCC	1st line
Bavencio/Inlyta	Avelumab/Axitinib	Immunotherapy + Targeted Therapy Oral and Infusion	EMD Serono/ Pfizer	2019 approval for first line treatment of metastatic RCC	1st line
Lenvima/Afinitor	Lenvatinib/ Everolimus	Targeted Therapy: TKI, VEGF inhibitor + mTOR Inhibitor Oral medication	Eisai	2016 approval for metastatic RCC patients following one prior anti-angiogenic therapy	2nd line
Opdivo	Nivolumab	Immunotherapy: Anti-PD1 Checkpoint-inhibitor infusion	Bristol Myers Squibb	2016 approval for metastatic RCC patients following one prior anti-angiogenic therapy	2nd line
Inlyta	Axitinib	Targeted Therapy: TKI, VEGF inhibitor Oral medication	Pfizer	2012 approval for metastatic RCC after failure of one prior systemic therapy	2nd line or 1st line in combination with immunotherapy
Fotivda	Tivozanib	Targeted Therapy: TKI, VEGF inhibitor Oral medication	AVEO Oncology	2021 approval for treatment of relapsed or refractory kidney cancer	3rd line
Welireg	Belzutifan	Targeted Therapy: HIF2a Inhibitor	Merck	2024 approval for treatment following immunotherapy and targeted VEGF treatment	3rd line
Cabometyx	Cabozantinib	Targeted Therapy: TKI, VEGF and c-MET inhibitor Oral medication	Exelixis	2016 approval for metastatic RCC after prior therapy; 2017 approval for first line metastatic RCC	2nd line; 1st line for patients ineligible for immunotherapy
Votrient	Pazopanib	Targeted Therapy: TKI, VEGF inhibitor Oral medication	Novartis	2012 approval for metastatic RCC	2nd line; 1st line for patients ineligible for immunotherapy
Sutent	Sunitinib	Targeted Therapy: Tyrosine-Kinase inhibitor (TKI) or VEGF inhibitor Oral medication	Pfizer	2006 approval for metastatic renal cell carcinoma (RCC); 2017 approval for RCC at high risk of recurrence	2nd line; 1st line for patients ineligible for immunotherapy, and as adjuvant treatment
Afinitor	Everolimus	Targeted Therapy: mTOR-Inhibitor Oral medication	Novartis	2009 approval for metastatic RCC after failure of treatment with sunitinib or sorafenib	2nd or later line, now primarily in combination with Lenvima
Torisel	Temsirolimus	Targeted Therapy: mTOR-inhibitor Infusion	Pfizer	2007 approval for metastatic RCC	Approved for poor risk 1st line for select patients; but now rarely used given alternatives
Avastin/ Interferon (IFN)	Bevacizumab/ Interferon alfa	VEGF-Antibody + immunotherapy Infusion/ subcutaneous injection	Genentech	2009 approval for metastatic RCC	1st line approval, rarely used given limited efficacy and IFN side effects
Nexavar	Sorafenib	Targeted Therapy: TKI, VEGF inhibitor Oral medication	Bayer	2005 approval for metastatic RCC	Late line
Proleukin	Aldesleukin (high-dose Interleukin-2 IL-2, HDIL-2)	Immunotherapy Inpatient Infusion	Prometheus	1992 approval for metastatic RCC	Remains a treatment option with curative potential in selected patients